Status:
COMPLETED
Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Prostate Cancer Foundation
Conditions:
Prostate Cancer
Eligibility:
MALE
40-75 years
Phase:
NA
Brief Summary
This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program...
Detailed Description
This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program...
Eligibility Criteria
Inclusion
- Phase 1
- All recruited participants must have owned a smartphone for \>1 year
- English-speaking.
- Patients with prostate cancer aged between 40-75 years will be considered.
- No specific timeframe after prostate cancer diagnosis will be required for these patients.
- No limitations regarding their disease characteristics will be imposed (e.g. metastatic disease).
- Patients may or may not be currently receiving treatment Staff members will be recruited from
- Dana-Farber Cancer Institute Department of Medical Oncology,
- Brigham and Women's Hospital, Department of Surgery. Staff members aged between 40-75 years old will be considered. Phase 2
- Men diagnosed with prostate cancer presenting to DF/BWHCC
- About to initiate ADT for the first time will be considered.
- Age range 40-75-years
- The ability to walk 400 m
- Medical clearance from their primary physician
- English speaking
- Cognitively alert
- Literate
- Ability to read or hear with or without contacts/glass and hearing aid
- Ownership of a smartphone for \>1yr
Exclusion
- Men who have been under a rigorous structured exercise regime, such as individuals who engage in more than 900 minutes of moderate physical activity per week in the last 6 months will not be considered
- Post-ADT treatment
- Planned systemic chemotherapy
- Planned treatment with abiraterone or enzalutamide
- Bone metastases
- Acute illness
- Any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put them at risk from exercising
- Subordinates to the PI
Key Trial Info
Start Date :
July 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 10 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03761160
Start Date
July 16 2019
End Date
July 10 2020
Last Update
June 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215